Compare Stocks: CMPX, ACRS, IRWD, and YDES

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$3.75 -2.1%	$5.11	$2.10 ▼ $6.60	$535.53M	0.87	3.91 million shs	2.29 million shs
CMPX Compass Therapeutics	$0.76 -5.1%	$1.62	$0.75 ▼ $6.88	$144.34M	1.02	5.56 million shs	2.13 million shs
IRWD Ironwood Pharmaceuticals	$3.46 -3.1%	$4.03	$1.47 ▼ $5.78	$589.91M	0.21	1.83 million shs	1.26 million shs
YDES YD Bio	$4.95 +16.7%	$4.94	$1.70 ▼ $18.57	$300.15M	-1.55	236,431 shs	105,142 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+0.52%	+9.74%	-33.04%	-26.77%	+69.47%
CMPX Compass Therapeutics	-1.60%	-10.62%	-35.36%	-61.28%	-80.73%
IRWD Ironwood Pharmaceuticals	+0.56%	-5.31%	-21.19%	-3.77%	+127.39%
YDES YD Bio	-26.52%	-37.09%	+50.35%	+89.29%	+423,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$3.75 -2.1%	$5.11	$2.10 ▼ $6.60	$535.53M	0.87	3.91 million shs	2.29 million shs
CMPX Compass Therapeutics	$0.76 -5.1%	$1.62	$0.75 ▼ $6.88	$144.34M	1.02	5.56 million shs	2.13 million shs
IRWD Ironwood Pharmaceuticals	$3.46 -3.1%	$4.03	$1.47 ▼ $5.78	$589.91M	0.21	1.83 million shs	1.26 million shs
YDES YD Bio	$4.95 +16.7%	$4.94	$1.70 ▼ $18.57	$300.15M	-1.55	236,431 shs	105,142 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+0.52%	+9.74%	-33.04%	-26.77%	+69.47%
CMPX Compass Therapeutics	-1.60%	-10.62%	-35.36%	-61.28%	-80.73%
IRWD Ironwood Pharmaceuticals	+0.56%	-5.31%	-21.19%	-3.77%	+127.39%
YDES YD Bio	-26.52%	-37.09%	+50.35%	+89.29%	+423,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	202.22% Upside
CMPX Compass Therapeutics	2.76	Moderate Buy	$10.25	1,246.91% Upside
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	80.15% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CMPX, ACRS, IRWD, and YDES Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/8/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C) ➝ Hold (C+)
9/25/2026	IRWD Ironwood Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/23/2026	CMPX Compass Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/23/2026	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$4.00
9/23/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$4.00
9/23/2026	CMPX Compass Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/23/2026	CMPX Compass Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Outperform	$4.00
9/22/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$5.00 ➝ $1.00
9/22/2026	CMPX Compass Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/21/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	66.96	N/A	N/A	$0.85 per share	4.41
CMPX Compass Therapeutics	$850K	161.23	N/A	N/A	$1.11 per share	0.69
IRWD Ironwood Pharmaceuticals	$296.15M	1.93	$0.25 per share	13.87	($1.61) per share	-2.15
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	4.58	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CMPX, ACRS, IRWD, and YDES Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	IRWD Ironwood Pharmaceuticals	$0.3233	N/A	N/A	N/A	$119.99 million	N/A
11/5/2026	Q3 2026	ACRS Aclaris Therapeutics	-$0.16	N/A	N/A	N/A	$1.23 million	N/A
11/4/2026	Q3 2026	CMPX Compass Therapeutics	-$0.12	N/A	N/A	N/A	$0.23 million	N/A
9/1/2026	Q2 2026	YDES YD Bio	N/A	$0.05	N/A	$0.0450	N/A	$0.42 million
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
CMPX Compass Therapeutics	N/A	11.22	11.22
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CMPX Compass Therapeutics	68.43%
IRWD Ironwood Pharmaceuticals	N/A
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
CMPX Compass Therapeutics	18.70%
IRWD Ironwood Pharmaceuticals	9.30%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	73	139.82 million	133.11 million	Optionable
CMPX Compass Therapeutics	39	180.09 million	146.41 million	Optionable
IRWD Ironwood Pharmaceuticals	100	165.24 million	149.87 million	Optionable
YDES YD Bio	14	70.79 million	N/A	N/A

CMPX, ACRS, IRWD, and YDES Headlines

Recent News About These Companies

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

October 20 at 8:00 AM | globenewswire.com

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

October 6, 2026 | globenewswire.com

Cours YD Bio Limited

September 24, 2026 | zonebourse.comZ

YD Bio (NASDAQ:YDES) CEO Ethan Phd Shen Purchases 3,100 Shares of Stock

September 11, 2026 | insidertrades.com

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1, 2026 | finet.hkF

YD Bio Ltd (YDES)

September 1, 2026 | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1, 2026 | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, ACRS, IRWD, and YDES Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$3.75 -0.08 (-2.09%)

Closing price 04:00 PM Eastern

Extended Trading

$3.76 +0.00 (+0.13%)

As of 07:30 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Compass Therapeutics NASDAQ:CMPX

$0.76 -0.04 (-5.05%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 +0.02 (+2.10%)

As of 07:30 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals NASDAQ:IRWD

$3.46 -0.11 (-3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$3.53 +0.07 (+2.02%)

As of 07:57 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

YD Bio NASDAQ:YDES

$4.95 +0.71 (+16.75%)

Closing price 04:00 PM Eastern

Extended Trading

$5.03 +0.08 (+1.60%)

As of 07:30 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, ACRS, IRWD, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, ACRS, IRWD, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, ACRS, IRWD, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, ACRS, IRWD, and YDES Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Compass Therapeutics NASDAQ:CMPX

Ironwood Pharmaceuticals NASDAQ:IRWD

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, ACRS, IRWD, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, ACRS, IRWD, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, ACRS, IRWD, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, ACRS, IRWD, and YDES Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Compass Therapeutics NASDAQ:CMPX

Ironwood Pharmaceuticals NASDAQ:IRWD

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools